(Q37380504)

20 August 2017

1 reference

title

Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice (English)

1 reference

20 August 2017

Nancy Bohannon

1

1 reference

PubMed ID

19179812

20 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

20 August 2017

Postgraduate Medicine

1 reference

20 August 2017

121

1 reference

20 August 2017

1

1 reference

20 August 2017

40-45

1 reference

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

20 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Long-range enhancers are required to maintain expression of the autoantigen islet-specific glucose-6-phosphatase catalytic subunit-related protein in adult mouse islets in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

Partial pancreatectomy in adult humans does not provoke beta-cell regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.01.1953

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.01.1953

1 reference

20 August 2017

1 reference

PubMed ID

19179812